Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Corneal collagen cross-linking with iontophoresis (I-CXL): 12 months of follow-up study

Poster Details

First Author: E. Interlandi ITALY

Co Author(s):    F. Pellegrini   C. Gabriella   C. Gianluca   P. Giovanni           

Abstract Details


to assess long-term efficacy and safety of transepithelial corneal collagen cross-linking with iontophoresis (I-CXL) in patients affected by progressive keratoconus after 12 months of follow-up.


Ophthalmology Department, “De Gironcoli” Hospital of Conegliano (TV), Italy.


clinica data from 37 patients (39 eyes) affected by progressive keratoconus treated by I-CXL were retrospectively analyzed. In all cases I-CXL was performed with Iontofor-CXL device and riboflavin 0,1% RICROLIN+ (SOOFT Italia S.p.A.). BCVA, corneal astigmatism, maximum keratometry (Kmax), thinnest corneal thickness, measured by Pentacam, were analyzed at baseline and at 3, 6 and 12 months after surgery. Endothelium cell count was measured in all patients before surgery and at 12 months postoperatively. The occurrence of I-CXL related side effects was moreover evaluated.


the mean age of recruited patients (24 males and 13 females) at surgery time was 24,72 years (7,13 SD) including six patients younger than 18 years (range: 12 to 17 years). After 12 months of follow-up BCVA, even not significantly, slightly improved in 53,8% of treated eyes (p=0.1267). Corneal astigmatism and thickness at the thinnest point remained stable while K max significantly improved in 74,3 % of eyes with a final mean value of 49,54D (4,49 SD) compared with 53,80D (5,09 SD) at baseline (p=0,00019). None of the patients showed progression of keratoconus neither I-CXL related adverse effects during whole follow-up.


The results of this study demonstrated I-CXL with RICROLIN+ to be an effective and safe procedure able to stabilize clinical course and to improve significantly Kmax value of our patients after one-year follow-up. I-CXL can be considered a valid conservative approach in patients affected by progressive keratoconus.

Financial Disclosure:


Back to Poster listing